For example, nilotinib (Tasigna), a Bcr-Abl inhibitor approved for therapy of chronic myelogenous leukemia (CML) has been shown to inhibit the function of ABCB1-, ABCG2-, and ABCC10 transporters and reverses drug resistance [28,29]. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.